FIVE-YEAR CLINICAL OUTCOME AFTER IMPLANTATION OF SIROLIMUS-ELUTING STENTS VERSUS PACLITAXEL-ELUTING STENTS IN UNSELECTED PATIENTS WITH CORONARY ARTERY DISEASE: KOMATE DES REGISTRY  by Ko, Young-Guk et al.
    
 i2 SUMMIT   
A193.E1804 
JACC March 9, 2010
Volume 55, issue 10A
FIVE-YEAR CLINICAL OUTCOME AFTER IMPLANTATION OF SIROLIMUS-ELUTING STENTS VERSUS 
PACLITAXEL-ELUTING STENTS IN UNSELECTED PATIENTS WITH CORONARY ARTERY DISEASE: KOMATE 
DES REGISTRY
i2 Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 3:30 p.m.-4:30 p.m.
Session Title: DES II, Restenosis, Left Main and Outcomes
Abstract Category: PCI - DES
Presentation Number: 2502-430
Authors: Young-Guk Ko, Jung-Sun Kim, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jnag, Pil Ki Min, Young Won Yoon, Bum-Kee Hong, Byoung Kwon 
Lee, Hyuck Moon Kwon, Severance Cardiovascular Hospital, Seoul, South Korea, Gangnam Severance Hospital, Seoul, South Korea
Background: The purpose of the study was to compare long-term clinical outcomes of Siroliums-eluting stents (SES) and paclitaxel-eluting stents 
(PES) in a multicenter registry. 
Methods: We investigated 5-year clinical outcomes of SES (n=671) versus PES (n=284) in an unselected patient population treated from Dec 
2002 to Dec 2004. The primary endpoint was the incidence of major adverse cardiac events (MACE) including cardiac death, myocardial infarction 
(MI), and target vessel revascularization (TVR). 
Results: Baseline clinical characteristics were similar between the two groups except lesion length (SES: 23.2±7.7 vs. PES: 20.6±7.3 mm, 
p<0.001) and stented length (SES: 24.9±6.4 vs. PES: 22.58±6.4 mm, p<0.001). At 1 year the MACE occurred in 4.6% of the SES group vs. 10.0% of 
the PES group (p<0.001). Higher incidence of MACE in the PES group at 1 year was mainly due to higher incidence of TVR (3.5% vs. 8.9%, p<0.001). 
However, at 5 years the cumulative survival free of MACE in the SES group was 86.2% versus 85.5% in the PES group (Log-rank p=0.207). At 5 years 
the TVR was 9.5% in the SES group vs. 11.5% in the PES group (p=NS). Incidence of cardiac death or MI was not different between the two groups. 
Conclusions: SES showed better clinical outcomes at 1 year due to lower incidence of TVR. However, the superiority of SES over PES diminished 
gradually over the 5-year follow-up, because SES had further gradual increase in TVR beyond 1 year. 
